News Center
December 14, 2021
Variantyx Winter Holiday Hours of Operation
- By Variantyx, Inc
- Posted in General Company Updates
Valued Customers, We would like to update you on our winter holiday hours of operation: Our offices will be closed...
November 12, 2021
Variantyx and Robert-Bosch Hospital team up to improve personalized oncology treatment
- By STUTTGART
- Posted in General Company Updates
STUTTGART, Germany, Nov. 15, 2021 PRNewswire Robert Bosch Venture Capital GmbH, the corporate venture capital company of the Bosch Group, has...
August 31, 2021
ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing
- By Variantyx, Inc
- Posted in Secondary & Incidental Findings
ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing. ...
May 11, 2021
Variantyx Expands Into Prenatal, Cancer Testing
- By Variantyx
- Posted in General Company Updates
Genomeweb | May 11, 2021 Variantyx, a genetic testing company offering clinical whole-genome sequencing-based assays, is expanding its menu to...
March 15, 2021
Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders
- By Variantyx
- Posted in General Company Updates
March 15, 2021 Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding...
February 27, 2021
Whole-genome sequencing and health insurance
By Daryl Spinner, PhD, MBA In the realm of genetic testing, insurance payers have been reluctant to recognize that there...
February 8, 2021
Industry Voices – Whole-genome sequencing ultimately benefits payers
- By Daryl Spinner, PhD, MBA
- Posted in Article
When solving a problem, taking a step back and looking at the big picture is often a wise tactic. In...
January 26, 2021
Unavoidable vs optional incidental findings: What you need to know
- By Variantyx, Inc
- Posted in Secondary & Incidental Findings
Given that genome sequencing has the potential to identify tens of thousands of variants in every patient sample tested, our...
January 26, 2021
Variantyx Launches Its WGS-Based Prenatal Test for High-Risk Pregnancies, Enters Women’s Health Market
- By Variantyx
- Posted in General Company Updates
January 26, 2021 Variantyx, a leader in high complexity hereditary disease testing, announced today that it will launch its Genomic Unity®...
January 20, 2021
Ethics in Whole Genome Sequencing
By Toni Lewis The use of whole-genome sequencing (WGS) in diagnostic testing brings up the topic of secondary findings or...